Mandatory Part 11 Risk Assessment Could Cost Industry Billions

Washington Drug Letter
KEYWORDS FDA / Part 11
A A

The drug, biologics and device industries could face billions in additional costs if the FDA requires risk analysis to be part of electronic recordkeeping regulations, an industry consultant says.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00